We reviewed the records of 36 patients with medically inoperable stage l-ll non-small cell lung carcinoma who were treated with radiotherapy. The median dose to the target was 60 Gy with conventional fractionation. Fifteen patients were treated without elective irradiation fields, while the remaining 21 were treated with extended fields including elective mediastinal regional lymph nodes. The overall survival rates at three and five years were 32.3% and 18.8%, the cause-specific survival rates were 40.9% and 27.3%, and the local control rates were 31.7% and 23.8%, respectively. In multivariate analysis the radiation dose had a marginally significant influence on the cause-specific survival, while tumor size had a significant influence on the local control rate. Only one patient had relapse in the regional mediastinal lymph nodes as the only site of metastasis. We conclude that the dose used in the present study is inadequate and recommend that further efforts be made to improve local control by dose escalation within a small target volume.
KrolA.D.G., AussemsP., NoordijkE.M., HermansJ., LeerJ.W.H.: Local irradiation alone for peripheral stage I lung cancer: could we omit the elective regional nodal irradiation?Int J Radiat Oncol Biol Phys,3.4: 297–302, 1996.
2.
SlotmanB.J., AntonisseI.E., NjoK.H.: Limited field irradiation in early stage (T1-2N0) non-small cell lung cancer.Radiother Oncol,41: 41–44, 1996.
3.
SibleyG.S.: Radiotherapy for patients with medically inoperable stage I non-small cell lung carcinoma: smaller volumes and higher doses – a review.Cancer,82: 433–438, 1998.
4.
DosoretzD.E., KatinM.J., BlitzerP.H., RubensteinJ.H., SaleniusS., RashidM., DosaniR.A., MestasG., SiegelA.D., ChadhaT.T.: Radiation therapy in the management of medically inoperable carcinoma of the lung: results and implications for future treatment strategies.Int J Radiat Oncol Biol Phys,24: 3–9, 1992.
5.
DosoretzD.E., GalmariniD., RubensteinJ.H., KatinM.J., BlitzerP.H., SaleniusS.A., DosaniR.A., RashidM., MestasG., HannanS.E.: Local control in medically inoperable lung cancer: an analysis of its importance in outcome and factors determining the probability of tumor eradication.Int J Radiat Oncol Biol Phys,27: 507–516, 1993.
6.
MoritaK., FuwaN., SuzukiY., NishioM., SakaiK., TamakiY., NiibeH., ChujoM., WadaS., SugiharaT., KiteM.: Radical radiotherapy for medically inoperable non-small cell lung cancer in clinical stage I: a retrospective analysis of 149 patients.Radiother Oncol,49: 31–36, 1997.
GaudenP.H., GebskiV.J., TripconyL.: The curative treatment by radiotherapy alone of stage I non-small carcinoma of the lung.Chest,108: 1278–1282, 1995.
UematsuM., ShiodaA., TaharaK., FukuiT., YamamotoF., TsumatoriG., OzekiY., AokiT., WatanabeM., KusanoS.: Focal, high dose and fractionated modified stereotactic radiation therapy for lung carcinoma patients. A preliminary experience.Cancer,82: 1062–1070, 1998.
13.
CoxJ.D., StetzJ., PajakT.F.: Toxicity criteria of the radiation therapy oncology group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC).Int J Radiat Oncol Biol Phys,31: 1341–1346, 1995.
MartiniN., BurtM.E., BainsM.S., MeCormackP.M., RuschV.W., GinbergR.J.: Survival after resection of stage II non-small cell lung cancer.Ann Thorac Surg,54: 460–466, 1992.
16.
ShahR., SabanahanS., RichardsonJ., MearnsA.J., GouldenC.: Results of surgical treatment of stage I and II lung cancer.J Cardiovasc Surg,37: 169–172, 1996.
17.
RosenthalS.A., CurranW.J.Jr., HerbertS.H., HugesE.N., SandlerM.H., StaffordP.M., McKennaW.G.: Clinical stage II non-small cell lung cancer treated with radiation therapy alone. The significance of clinically staged ipsilateral hilar adenopathy (N1 disease).Cancer,70: 2410–2417, 1992.
18.
WürschmidtF., BünemannH., BünemannC., Beck-BornholdtH.P., HeilmannH.P.: Inoperable non-small cell lung cancer: a retrospective analysis of 427 patients treated with high-dose radiotherapy.Int J Radiat Oncol Biol Phys,28: 583–588, 1994.
19.
JeremicB., ShibamotoY., AcimovicL., MilisavljevicS.: Hyperfractionated radiotherapy for clinical stage II non-small cell lung cancer.Radiother Oncol,51: 41–145, 1999.
20.
ZhangH.X., YinW.B., ZhangL.J., YangZ.Y., ZhangZ.X., WangM.: Curative radiotherapy of early operable non-small cell lung cancer.Radiother Oncol,14: 89–94, 1989.
